

Consulting Services

Special Designations/Programs
-
Orphan Drug Designation [ODD]
-
EMA Priority Medicines [PRIME]
-
Breakthrough Designation [BTD]
-
Regenerative Medicine Advanced Therapy [RMAT]
-
Fast Track Designation
-
Accelerated Approval

Regulatory Management
-
Interim head of regulatory
-
Team expansion and management
-
Advice on Regulatory Operations and Regulatory CMC
-
Regulatory systems, infrastructure, Quality Systems

Health Authority Interactions
-
Support for global Health Authority meetings and scientifc advice
-
Milestone meetings (pre-IND, end-of-Phase, pre-NDA/BLA)
-
Briefing documents
-
Meeting preparation

Milestone Submissions
-
Initial IND
-
Pediatric Study Plan [PSP] and Paediatric Investigational Plan [PIP]
-
NDA/BLA/MAA

Regulatory Strategy
-
Regulatory risk assessment
-
Novel endpoints strategy
-
Due diligence
-
Global regulatory lead

Routine Submissions
-
Global CTAs and amendments
-
DSURs/Annual Reports
-
CMC amendments
-
Nonclinical study reports
-
Investigator's Brochures
-
Investigator updates
